<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04286815</url>
  </required_header>
  <id_info>
    <org_study_id>CHCMU gene therapy</org_study_id>
    <nct_id>NCT04286815</nct_id>
  </id_info>
  <brief_title>Gene Therapy for X Linked Severe Combined Immunodeficiency</brief_title>
  <official_title>Gene Therapy for X Linked Severe Combined Immunodeficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital of Chongqing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital of Chongqing Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A safety and efficacy clinical study of a lentiviral vector to transfer IL2RG complementary
      DNA to bone marrow stem cells in ten children with genetic diagnosed X-SCID（severe combined
      immune deficiency ）.The ten children will be followed for 3-5 years and be evaluated by
      clinical characteristics, vector marking (vector copy number per cell) in blood and bone
      marrow cells, immune reconstitution vector insertion-site patterns and so on.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2020</start_date>
  <completion_date type="Anticipated">May 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1-year survival rate 1-year survival rate</measure>
    <time_frame>one year after gene therapy of last recruited patient</time_frame>
    <description>1-year survival rate of 10 recruited patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>3-year survival rate</measure>
    <time_frame>three years after gene therapy of last recruited patient</time_frame>
    <description>3-year survival rate of 10 recruited patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>5-year survival rate</measure>
    <time_frame>five years after gene therapy of last recruited patient</time_frame>
    <description>5-year survival rate of 10 recruited patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Growth velocity after gene therapy,weight in kilograms, height in meters</measure>
    <time_frame>through study completion, an average of 2 year</time_frame>
    <description>Body weight and height of patients will be assessed prior to (month 0) and post gene therapy,weight in kilograms, height in meters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vector marking (vector copy number per cell) in blood and bone marrow cells</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>vector marking in T cells, B cells, NK cells, myeloid cells, and bone marrow progenitors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute numbers of peripheral-blood immune-cell subsets</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Absolute numbers of peripheral-blood immune-cell subsets，as determined by means of standard flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantity of DNA T-cell-receptor excision circles (TRECs) in peripheral-blood mononuclear cells</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>Quantity of DNA T-cell-receptor excision circles (TRECs) in peripheral-blood ，as determined by means of quantitative polymerase chain reaction (PCR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum immunoglobulins levels</measure>
    <time_frame>through study completion, an average of 2 year</time_frame>
    <description>Serum immunoglobulins levels will be reported IgM（immunoglobulin M） in mg/dL Serum immunoglobulins levels will be reported IgM in mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients without intravenous immune globulin supplementation</measure>
    <time_frame>through study completion, an average of 2 year</time_frame>
    <description>Number of patients without intravenous immune globulin supplementation after gene therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who has a response to vaccines</measure>
    <time_frame>through study completion, an average of 2 year</time_frame>
    <description>Number of patients who has a response to vaccines after gene therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who recovers from previous infection（virus and bacteria）</measure>
    <time_frame>through study completion, an average of 2 year</time_frame>
    <description>Number of patients who recovers from previous infection（virus and bacteria）after gene therapy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Gene Therapy</condition>
  <arm_group>
    <arm_group_label>Experimental Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>a lentiviral vector to transfer IL2RG complementary DNA to bone marrow stem cells in ten children with genetic diagnosed X-SCID（severe combined immune deficiency）.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lentiviral Vector Gene Therapy</intervention_name>
    <description>Lentiviral vector to transfer IL2RG complementary DNA to patients'bone marrow stem cells</description>
    <arm_group_label>Experimental Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. X-SCID patients diagnosed by IL2RG single gene mutation

          2. No HLA（human leukocyte antigen） matching donor

          3. Hematopoietic stem cell transplantation failed and the time from transplantation was
             more than 18 months

          4. Severe and persistent refractory infections

          5. Life expectancy of &gt; : 4 months

          6. HIV PCR in peripheral blood was negative

          7. the children and their families signed informed consent and were willing to enter the
             clinical trial and complete follow-up

        Exclusion Criteria:

          1. The patient has diagnosed with hematological malignant diseases

          2. Received chemotherapy within 3 months

          3. HIV infection or HBV（hepatitis B virus） infection

          4. The patient or his first-degree relative has developed a malignant tumor within the
             age of 18 or has been diagnosed with malignant tumor prone genes

          5. Although the patient with X-SCID was diagnosed as IL2RG single gene mutation , the
             clinical phenotype was not severe, so they could continue to wait for the donor
             search;

          6. Patients whose family members have no intention to continue the follow-up treatment in
             any link
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaodong Zhao, PHD</last_name>
    <role>Study Director</role>
    <affiliation>Assistant President of Children's Hospital of Chongqing Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaodong Zhao, PHD</last_name>
    <phone>18623070626</phone>
    <email>zhaoxd530@aliyun.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Qiling Xu, MD</last_name>
    <phone>18581059910</phone>
    <email>272864835@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Hospital of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400014</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaodong Zhao, PhD</last_name>
      <phone>18623070626</phone>
      <email>zhaoxd530@aliyun.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Mamcarz E, Zhou S, Lockey T, Abdelsamed H, Cross SJ, Kang G, Ma Z, Condori J, Dowdy J, Triplett B, Li C, Maron G, Aldave Becerra JC, Church JA, Dokmeci E, Love JT, da Matta Ain AC, van der Watt H, Tang X, Janssen W, Ryu BY, De Ravin SS, Weiss MJ, Youngblood B, Long-Boyle JR, Gottschalk S, Meagher MM, Malech HL, Puck JM, Cowan MJ, Sorrentino BP. Lentiviral Gene Therapy Combined with Low-Dose Busulfan in Infants with SCID-X1. N Engl J Med. 2019 Apr 18;380(16):1525-1534. doi: 10.1056/NEJMoa1815408.</citation>
    <PMID>30995372</PMID>
  </reference>
  <reference>
    <citation>Hacein-Bey-Abina S, Hauer J, Lim A, Picard C, Wang GP, Berry CC, Martinache C, Rieux-Laucat F, Latour S, Belohradsky BH, Leiva L, Sorensen R, Debré M, Casanova JL, Blanche S, Durandy A, Bushman FD, Fischer A, Cavazzana-Calvo M. Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med. 2010 Jul 22;363(4):355-64. doi: 10.1056/NEJMoa1000164.</citation>
    <PMID>20660403</PMID>
  </reference>
  <reference>
    <citation>De Ravin SS, Wu X, Moir S, Anaya-O'Brien S, Kwatemaa N, Littel P, Theobald N, Choi U, Su L, Marquesen M, Hilligoss D, Lee J, Buckner CM, Zarember KA, O'Connor G, McVicar D, Kuhns D, Throm RE, Zhou S, Notarangelo LD, Hanson IC, Cowan MJ, Kang E, Hadigan C, Meagher M, Gray JT, Sorrentino BP, Malech HL, Kardava L. Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency. Sci Transl Med. 2016 Apr 20;8(335):335ra57. doi: 10.1126/scitranslmed.aad8856. Erratum in: Sci Transl Med. 2016 Jun 1;8(341):341er5.</citation>
    <PMID>27099176</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 23, 2020</study_first_submitted>
  <study_first_submitted_qc>February 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2020</study_first_posted>
  <last_update_submitted>March 26, 2020</last_update_submitted>
  <last_update_submitted_qc>March 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital of Chongqing Medical University</investigator_affiliation>
    <investigator_full_name>mingfeng hu</investigator_full_name>
    <investigator_title>Resident physician</investigator_title>
  </responsible_party>
  <keyword>Gene Therapy</keyword>
  <keyword>X Linked Severe Combined Immunodeficiency</keyword>
  <keyword>Lentiviral Vector</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Severe Combined Immunodeficiency</mesh_term>
    <mesh_term>X-Linked Combined Immunodeficiency Diseases</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

